133 related articles for article (PubMed ID: 12101579)
21. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
22. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
23. [A new, more expensive agent against ovarian cancer. Worth its price?].
Högberg T; Karlsson G; Ridderheim M; Boman K; Frankendal B; Horvath G; Sorbe B; Strang P; Rosenberg P
Lakartidningen; 1997 Jan; 94(1-2):21-4. PubMed ID: 9053597
[No Abstract] [Full Text] [Related]
24. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
26. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
27. [Paclitaxel, a new anticancer drug].
Jekunen A; Lehtovirta P; Pyrhönen S
Duodecim; 1994; 110(13):1235-40. PubMed ID: 7497933
[No Abstract] [Full Text] [Related]
28. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
30. Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.
Wang KL; Yang YC; Lai JC; Tsai TH; Lin CP; Wu YT; Chen YY; Wang SC; Chen YJ
Drug Dev Ind Pharm; 2010 Oct; 36(10):1253-8. PubMed ID: 20818963
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
32. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
33. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
34. [Paclitaxel should be included in standard therapy of ovarian carcinoma].
Tropé C; Kaern J; Saeter G; Gore M
Tidsskr Nor Laegeforen; 2003 Nov; 123(21):3083-4. PubMed ID: 14618184
[No Abstract] [Full Text] [Related]
35. [Taxans in the treatment of ovarian cancer].
Tuxen MK; Dombernowsky P
Ugeskr Laeger; 1996 Jul; 158(27):3951-2. PubMed ID: 8701514
[No Abstract] [Full Text] [Related]
36. [Taxol and ovarian adenocarcinomas].
Marty M; Extra JM; Culine S; Rousseau F
Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165
[No Abstract] [Full Text] [Related]
37. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.
Xi Z; Kaern J; Davidson B; Klokk TI; Risberg B; Tropé C; Saatcioglu F
Gynecol Oncol; 2004 Jul; 94(1):80-5. PubMed ID: 15262123
[TBL] [Abstract][Full Text] [Related]
38. [Taxanes--a new generation of cytostatic drugs].
Diehl V; Steinmetz T
Med Klin (Munich); 1993 Nov; 88 Suppl 2():3. PubMed ID: 7907773
[No Abstract] [Full Text] [Related]
39. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
40. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]